Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mekinian Arsène, Meneses Sarah, Biard Lucie, Dagna Lorenzo, Novikov Pavel, Salvarani Carlo, Espitia Olivier, Sciscia Savino, Michaud Martin, Lambert Marc, Hernández-Rodríguez José, Schleinitz Nicolas, Awisat Abid, Puéchal Xavier, Aouba Achille, Munoz Pons Heloise, Smitienko Ilya, Gaultier Jean Baptiste, Edwige Le Mouel, Benhamou Ygal, Perlat Antoinette, Jego Patrick, Goulenok Tiphaine, Sacre Karim, Lioger Bertrand, Hassold Nolan, Broner Jonathan, Dufrost Virginie, Sene Thomas, Seguier Julie, Maurier Francois, Berthier Sabine, Belot Alexandre, Frikha Faten, Denis Guillaume, Audemard-Verger Alexandra, Koné-Paut Isabelle, Humbert Sebastien, Woaye-Hune Pascal, Tomelleri Alessandro, Baldissera Elena, Kuwana Masataka, Lo Gullo Alberto, Mukuchyan Vahan, Dellal Azeddine, Gaches Francis, Zeminsky Pierre, Marvisi Chiara, Alvarado Moya, Boiardi Luigi, Muratore Francesco, Vautier Mathieu, Campochiaro Corrado, Moiseev Sergey, Vieira Matheus, Cacoub Patrice, Fain Olivier, Saadoun David, French Takayasu Network
Аннотация
METHODS: We conducted a retrospective multicentre study across referral centres in France, Italy, Spain, Armenia, Israel, Japan, Tunisia, and Russia, analysing biologic targeted therapies in TAK from January 2017 to September 2019.
RESULTS: A total of 135 TAK patients who received ADA (n = 34) or IFX (n = 101) for at least 3 months were included. Baseline demographics, TAK characteristics and concurrent treatments were comparable, except for a higher rate of Numano type V in the ADA group. At 6 months, 71% achieved complete response (NIH <2 with <7.5 mg/day prednisone), including 68% on ADA and 73% on IFX (P = 0.8). The factors associated with complete response to TNF-α inhibitors at 6 months in univariate analysis were age <30 years, tobacco use, vascular signs at the biologic initiation, NIH ≥2, CRP >20 mg/l, a starting dose >20 mg/day of prednisone, but not the use of either IFX or ADA. The cumulative incidence of treatment failure was not significantly different between IFX and ADA patients. During the median [IQR] follow-up of 23 [17, 42] and 48 [25, 99] months in patients who received i.v. IFX and s.c. ADA, respectively, the risk of relapse at 12 months was 10.9% [0, 21.9] and 16.8% [8.64, 24.27], respectively. The overall incidence of revascularizations was not significantly different.
CONCLUSION: In this study, we confirm that IFX and ADA are both effective in TAK, without significant differences in the risk of relapse and revascularizations.